Alert

Alert Pro Chart

Immix Biopharma Inc. (IMMX)

NasdaqCM: IMMX · Real-Time Price · USD

10.97

+0.05 (0.46%)

At close: Aug 14, 2026, 3:59 PM

10.97

+0.00%

After-hours: 7:34 PM

0.46% (1D)

Bid	7.95
Market Cap	780.95M
Revenue (ttm)	n/a
Net Income (ttm)	-39.92M
Beta	0.11
EPS (ttm)	-0.88
PE Ratio (ttm)	n/a
Forward PE	-12.14
P/B (ttm)	6.90
P/S (ttm)	n/a
Earnings Date	n/a

Ask	13.4
Volume	1,263,691
Avg. Volume (20D)	1,878,943
Open	10.85
Previous Close	10.92
Day's Range	10.36 - 11.08
52-Week Range	1.94 - 12.14
Analyst	Strong Buy
Price Target	20 (82.32%)
Dividends	n/a
Ex-Dividend Date	n/a

About IMMX

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California....

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 16, 2021

Employees 21

Stock Exchange NasdaqCM

Ticker Symbol IMMX

Website https://www.immixbio.com

Full Company Profile

Financial Performance

In 2025, Immix Biopharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -29.44M, an increase of 36.21%.

Financial Statements

Analyst Forecast

According to 8 analyst ratings, the average rating for IMMX stock is "Strong Buy". The 12-month stock price forecast is 20, which is upside of 82.32% from the latest price.

Stock Forecasts

Earnings Surprise

Immix Biopharma has released their quarterly earnings on Aug 7, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.18 misses estimates by 0.00, with 18.18% YoY growth.

News

3 weeks ago · Investor's Business Daily

Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

1 month ago · Zacks

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

2 months ago · Simply Wall St.

Exploring 3 High Growth Tech Stocks in the US Market

Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying...

2 months ago · Zacks

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

3 months ago · Simply Wall St.

3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%

Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing envir...

Page 1 of 2

Immix Biopharma Inc. (IMMX)